Clinical Trials Directory

Trials / Conditions / PD-1 Antibody

PD-1 Antibody

12 registered clinical trials studyying PD-1 Antibody — 2 currently recruiting.

StatusTrialSponsorPhase
CompletedDEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
NCT04834674
Sichuan Cancer Hospital and Research InstitutePhase 2
RecruitingNeoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer
NCT05554276
Shanghai Jiao Tong University Affiliated Sixth People's HospitalPhase 2
Not Yet RecruitingL-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
NCT05775705
Beijing Friendship HospitalPhase 3
UnknownAnti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
NCT05461235
China Medical University, ChinaPhase 2
UnknownTislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Local
NCT05156788
Shanghai Zhongshan HospitalPhase 2
UnknownPD-1 Antibody Improve Mixed Chimerism
NCT04944511
Beijing Friendship HospitalN/A
CompletedTislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
NCT04507217
Sun Yat-sen UniversityPhase 2
UnknownA Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC
NCT04108013
Xuanwu Hospital, BeijingPhase 2
TerminatedPhase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in
NCT03777124
Jiangsu HengRui Medicine Co., Ltd.Phase 2
UnknownA Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
NCT03668496
Jiangsu HengRui Medicine Co., Ltd.Phase 3
UnknownPD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor
NCT02873390
Ningbo Cancer HospitalPhase 1 / Phase 2
UnknownPD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Sto
NCT02862028
Shanghai International Medical CenterPhase 1 / Phase 2